• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D filed by Kadmon Holdings, Inc.

    9/17/21 8:24:15 AM ET
    $KDMN
    Major Pharmaceuticals
    Health Care
    Get the next $KDMN alert in real time by email
    SC 13D 1 tm2127744d2_sc13d.htm SCHEDULE 13D

     

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D. C. 20549

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. )*

     

    Kadmon Holdings, Inc.

     

    (Name of Issuer)

     

    Common Stock, par value $.001

     

    (Title of Class of Securities)

     

    48283N106

     

    (CUSIP Number of Class of Securities)

     

    Alec N. Litowitz

    Magnetar Capital LLC

    1603 Orrington Ave.

    Evanston, Illinois 60201

    (847) 905-4400

     

    (Name, Address and Telephone Number of Person Authorized
    to Receive Notices and Communications)

     

    September 9, 2021

     

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a Statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D and is filing this Schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box.¨

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 240.13d-7(b) for other parties to whom copies are to be sent.

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 48283N106 SCHEDULE 13D Page 2 of 12

     

    1. 

    NAME OF REPORTING PERSON:

     

    Magnetar Financial LLC

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)       ¨

    (b)       x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8. 

    SHARED VOTING POWER

    9,871,249

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH

    10. 

    SHARED DISPOSITIVE POWER

    9,871,249

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,871,249

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.70%

    14.

    TYPE OF REPORTING PERSON

     

    IA; OO

     

     

     

    CUSIP No. 48283N106 SCHEDULE 13D Page 3 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Magnetar Capital Partners LP

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)       ¨

    (b)       x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7. 

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8. 

    SHARED VOTING POWER

    9,871,249

    EACH REPORTING

    PERSON

    9. 

    SOLE DISPOSITIVE POWER

    0

    WITH

    10. 

    SHARED DISPOSITIVE POWER

    9,871,249

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,871,249

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.70%

    14.

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

    CUSIP No. 48283N106 SCHEDULE 13D Page 4 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Supernova Management LLC

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

    (a)       ¨

    (b)       x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    7.

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    9,871,249

    EACH REPORTING

    PERSON

    9.

    SOLE DISPOSITIVE POWER

    0

    WITH

    10. 

    SHARED DISPOSITIVE POWER

    9,871,249

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,871,249

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.70%

    14.

    TYPE OF REPORTING PERSON

     

    HC; OO

     

     

     

    CUSIP No. 48283N106 SCHEDULE 13D Page 5 of 12

     

    1.

    NAME OF REPORTING PERSON:

     

    Alec N. Litowitz

     

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)       ¨

    (b)       x

    3.

    SEC USE ONLY

     

    4.

    SOURCE OF FUNDS

     

    OO

     

    5.

    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e) ¨

     

    6.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    7.

    SOLE VOTING POWER

    0

    BENEFICIALLY

    OWNED BY

    8.

    SHARED VOTING POWER

    9,871,249

    EACH REPORTING

    PERSON

    9.

    SOLE DISPOSITIVE POWER

    0

    WITH

    10.

    SHARED DISPOSITIVE POWER

    9,871,249

    11.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    9,871,249

    12.

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES

     

    ¨

    13.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

     

    5.70%

    14.

    TYPE OF REPORTING PERSON

     

    HC; IN

     

     

     

    SCHEDULE 13D

     

    item 1.security and issuer

     

    This Schedule 13D (this “Statement”) relates to the common stock, $0.001 par value (the “Shares”), of Kadmon Holdings, Inc., a company incorporated in Delaware (the “Company”). The principal executive offices of the Company is 450 East 29th Street, New York, NY 10016.

     

    Item 2.identity and background

     

    (a)           The persons filing this Statement are Magnetar Financial LLC, a Delaware limited liability company (“Magnetar Financial”), Magnetar Capital Partners LP, a Delaware limited partnership (“Magnetar Capital Partners”), Supernova Management LLC, a Delaware limited liability company (“Supernova Management”), and Alec N. Litowitz (“Mr. Litowitz”) (collectively, the “Reporting Persons”).

     

    This Statement relates to Shares held for the accounts of each of (i) Magnetar PRA Master Fund Ltd, a Cayman Islands exempted company (“PRA Master Fund”), (ii) Magnetar Constellation Fund II-PRA LP, a Delaware limited partnership (“Constellation Fund”), and (iii) Magnetar Systematic Multi-Strategy Master Fund Ltd, a Cayman Islands exempted company, (“Systematic Master Fund”), collectively (the “Funds”).

     

    Magnetar Financial is a Securities and Exchange Commission (“SEC”) registered investment adviser under Section 203 of the Investment Advisers Act of 1940, as amended, and manager of investment funds and managed accounts. Magnetar Financial serves as investment adviser to each of the Funds. In such capacity, Magnetar Financial exercises voting and investment power over the Shares held for the accounts of each of the Funds. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Financial. Supernova Management is the general partner of Magnetar Capital Partners. The manager of Supernova Management is Mr. Litowitz.

     

    (b)          The business address of each of the Reporting Persons is 1603 Orrington Avenue, 13th Floor, Evanston, Illinois 60201.

     

    (c)          Each of the Funds is a private investment fund; Magnetar Financial is a privately-held SEC registered investment adviser and manager of investment funds and managed accounts; Magnetar Capital Partners is a privately-held limited partnership and serves as the sole member and parent holding company of Magnetar Financial; Supernova Management is a privately-held limited liability company and is the general partner of Magnetar Capital Partners; and Mr. Litowitz is a citizen of the United States of America, manager of Supernova Management and Chief Executive Officer of Magnetar Financial.

     

    (d)          None of the Reporting Persons has, during the last five years, been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).

     

    (e)          None of the Reporting Persons has, during the last five years, been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction as a result of which such Reporting Person was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

     

     

    (f)           Magnetar Financial is a Delaware limited liability company. Magnetar Capital Partners is a Delaware limited partnership. Supernova Management is a Delaware limited liability company. Mr. Litowitz is a citizen of the United States of America.

     

    Item 3.source and amount of funds or other consideration

     

    The aggregate amount of funds used by the Reporting Persons in purchasing the 9,871,249 Shares reported herein on behalf of the Funds have come directly from the assets of the Funds, which may at any given time, have included margin loans made by brokerage firms in the ordinary course of business. The aggregate amount of funds used by the Reporting Persons in purchasing the Shares on behalf of the Funds was $90,104,373.12 (excluding commissions and other execution-related costs).

     

    ITEM 4.PURPOSE OF TRANSACTION

     

    The Reporting Persons acquired the 9,871,249 Shares reported herein on behalf of the Funds after the public announcement of the Merger Agreement (as defined below) for purposes of receiving the merger consideration described below upon consummation of the Merger (as described below).

     

    Each of the Reporting Persons reserves the right to acquire additional securities of the Company in the open market, in privately negotiated transactions, or otherwise, to dispose of all or a portion of the Shares and/or other securities reported in this Statement, or to change their intention with respect to any or all of the matters referred to in this Item 4.

     

    Other than as described above in this Item 4, the Reporting Persons do not have any plans or proposals that relate to, or would result in, any actions or events specified in clauses (a) through (j) of Item 4 to Schedule 13D.

     

    ITEM 5.INTEREST IN SECURITIES OF THE ISSUER

     

    The Company reported in their Form 8-K filed on September 7, 2021 that 173,331,781 Shares were issued and outstanding as of August 31, 2021.

     

    (a)           As of the close of business September 16, 2021, each of the Reporting Persons may have been deemed to have beneficial ownership of 9,871,249 Shares, which consisted of (i) 5,723,920 Shares held for the benefit of PRA Master Fund, (ii) 3,084,834 Shares held for the benefit of Constellation Fund; and (iii) 1,062,495 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 5.70% of the Shares.

     

    (b)          As of the close of business September 16, 2021, each of the Reporting Persons may have been deemed to share the power to vote and direct the disposition of 9,871,249 Shares, which consisted of (i) 5,723,920 Shares held for the benefit of PRA Master Fund, (ii) 3,084,834 Shares held for the benefit of Constellation Fund; and (iii) 1,062,495 Shares held for the benefit of Systematic Master Fund, and all such Shares represented beneficial ownership of approximately 5.70% of the Shares.

     

    (c)          Except as set forth on Schedule A attached hereto and Item 6, the Funds had no transactions in the Shares during the 60 days preceding the date of filing of this Statement. All of the transactions set forth on Schedule A attached hereto were effected in the ordinary course of business of Magnetar Financial for the accounts of each of the Funds. The transactions in the Shares set forth on Schedule A were effected in open market transactions on the NYSE and various other trading markets.

     

     

     

    As disclosed by the Company in the 8-K filed with the SEC on September 7, 2021:

     

    Agreement and Plan of Merger

     

    On September 7, 2021, Kadmon Holdings, Inc., a Delaware corporation (the “Company”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Sanofi, a French société anonyme (“Sanofi”), and Latour Merger Sub, Inc., a Delaware corporation and an indirect wholly owned subsidiary of Sanofi (“Merger Subsidiary”), providing for the merger of Merger Subsidiary with and into the Company (the “Merger”), with the Company surviving the Merger as a wholly owned subsidiary of Parent. Capitalized terms not otherwise defined have the meanings set forth in the Merger Agreement.

     

    The Company’s board of directors (the “Board”) has unanimously approved the Merger and the Merger Agreement and recommended that the stockholders of the Company adopt the Merger Agreement.

     

    (d)          No other person is known by the Reporting Persons to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any Shares that are beneficially owned by the Reporting Persons.

     

    ITEM 6.contracts, arrangements, understandings or relationships with respect to the securities of the issuer

     

    Pursuant to Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the Reporting Persons have entered into an agreement with respect to the joint filing of this Statement, and any amendment or amendments hereto.

     

    A client of Magnetar Financial has entered into a total return swap agreement giving it economic exposure to the Company.

     

    Magnetar Asset Management LLC (“Magnetar Asset Management”) is an SEC registered investment adviser and an affiliate of Magnetar Financial. Magnetar Capital Partners serves as the sole member and parent holding company of Magnetar Asset Management. Certain clients of Magnetar Asset Management have entered into total return swap agreements giving them economic exposure to the Company.

     

    Except as otherwise described herein, no contracts, arrangements, understandings or similar relationships exist with respect to the securities of the Company among or between the Reporting Persons or any other person or entity.

     

     

     

    ITEM 7.MATERIAL TO BE FILED AS EXHIBITS

     

    Exhibit No.Description
      
    99.1Joint Filing Agreement, dated as of September 17, 2021 among the Reporting Persons.

     

     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: September 17, 2021

     

      magnetar financial llc
       
      By: Magnetar Capital Partners LP, its Sole Member
       
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      magnetar capital partners lP
       
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager of Supernova Management LLC, the General Partner of Magnetar Capital Partners LP

     

      supernova management llc
       
      By: /s/ Alec N. Litowitz
        Name: Alec N. Litowitz
        Title: Manager

     

      /s/ Alec N. Litowitz
      Alec N. Litowitz

     

     

     

    SCHEDULE A

     

    Funds

     

    Date Number of Shares Bought Price Per Share($) (1)(2)
    9/8/2021 6,680,534 9.14488 (3)
    9/9/2021 3,087,837 9.09269 (4)
    9/10/2021 102,878 9.08803 (5)

     

    (1) Excludes commissions and other execution-related costs.

    (2) Upon request by the staff of the Securities and Exchange Commission, full information regarding the number of shares bought or sold (as the case may be) at each separate price will be provided.

    (3) Reflects a weighted average purchase price of $9.14488 per share, at prices ranging from $9.07 to $9.20 per share.

    (4) Reflects a weighted average purchase price of $9.09269 per share, at prices ranging from $9.07 to $9.13 per share.

    (5) Reflects a weighted average purchase price of $9.08803 per share, at prices ranging from $9.04 to $9.11 per share.

     

     

     

    EXHIBIT INDEX

     

    Exhibit No.  Description
        
        
    99.1  Joint Filing Agreement, dated as of September 17, 2021 among the Reporting Persons.

     

     

    Get the next $KDMN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $KDMN

    DatePrice TargetRatingAnalyst
    9/14/2021$13.00 → $9.50Buy → Neutral
    Mizuho
    9/9/2021$10.00 → $9.50Buy → Hold
    Jefferies
    7/19/2021$8.00 → $9.00Outperform
    Oppenheimer
    More analyst ratings

    $KDMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Flowers Cynthia Louise gifted 20,150 shares and returned $103,075 worth of shares to the company (10,850 units at $9.50), closing all direct ownership in the company

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:38 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Cohen David E

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:37:34 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 4 filed by Ryan John L

      4 - Kadmon Holdings, Inc. (0001557142) (Issuer)

      11/9/21 5:41:04 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

      Collaboration to unlock the therapeutic potential of ROCK2 inhibition for rare neurological diseases Couples Ovid capabilities in rare CNS development with Graviton's expertise in RhoA/ROCK2 signaling pathway to accelerate a series of clinical development programsDevelopment to focus on serious disorders that have few-to-no therapeutic options, including cerebral cavernous malformations and conditions presenting with seizuresOvid to invest $10 million in preferred equity in Graviton and will fund development programsTransaction has no milestone payments and Graviton is eligible for tiered double-digit royalties on commercial sales NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -

      5/1/23 6:00:00 AM ET
      $MGTX
      $OVID
      $KDMN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
      Major Pharmaceuticals
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kadmon Holdings downgraded by Mizuho with a new price target

      Mizuho downgraded Kadmon Holdings from Buy to Neutral and set a new price target of $9.50 from $13.00 previously

      9/14/21 7:13:20 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Holdings downgraded by Jefferies with a new price target

      Jefferies downgraded Kadmon Holdings from Buy to Hold and set a new price target of $9.50 from $10.00 previously

      9/9/21 5:30:28 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Oppenheimer reiterated coverage on Kadmon Holdings with a new price target

      Oppenheimer reiterated coverage of Kadmon Holdings with a rating of Outperform and set a new price target of $9.00 from $8.00 previously

      7/19/21 7:45:32 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $KDMN
    SEC Filings

    See more
    • SEC Form SC 13D filed by Kadmon Holdings, Inc.

      SC 13D - Kadmon Holdings, Inc. (0001557142) (Subject)

      9/17/21 8:24:15 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed by Kadmon Holdings, Inc. (Amendment)

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      5/28/21 5:04:26 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form SC 13G/A filed

      SC 13G/A - Kadmon Holdings, Inc. (0001557142) (Subject)

      2/17/21 3:12:07 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form 15-12B filed by Kadmon Holdings, Inc.

      15-12B - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/19/21 4:01:10 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:18 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • SEC Form EFFECT filed by Kadmon Holdings, Inc.

      EFFECT - Kadmon Holdings, Inc. (0001557142) (Filer)

      11/16/21 12:15:09 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Financials

    Live finance-specific insights

    See more
    • Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results

      - REZUROCK™ (belumosudil) 200 mg once daily (QD) tablets are now commercially available for shipment to prescribed patients in the United States -- Execution of strategic launch strategy underway; Third quarter REZUROCK net sales $12.2 million -- Sanofi acquisition of Kadmon expected to close 4Q 2021 -NEW YORK, NY / ACCESSWIRE / November 4, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the third quarter of 2021."The third quarter was an exceptional period for Kadmon culminating in the availability of REZUROCK to patients living with cGVHD and the significant milestones that were achieved in the months following

      11/4/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports Second Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / August 5, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the second quarter of 2021."The recent U.S. FDA approval of REZUROCK marked a transformative event for Kadmon and for patients living with cGVHD. REZUROCK represents a paradigm shift in the cGVHD treatment landscape by uniquely addressing both the immune and fibrotic components of the disease," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We look forward to bringing this meaningful new therapy to patients in the U.S. by the end of this month."Dr. Waksal added, "Our momentum continues as we advance our portfolio of p

      8/5/21 4:05:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care
    • Kadmon Provides Business Update and Reports First Quarter 2021 Financial Results

      NEW YORK, NY / ACCESSWIRE / May 6, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today provided a business update and reported financial and operational results for the first quarter of 2021."We continue to ramp up commercial launch preparation activities for belumosudil in anticipation of the PDUFA goal date of August 30, 2021. Labeling discussions with the FDA are progressing and we believe that belumosudil, if approved, will serve a critical, unmet need for patients with cGVHD," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "In addition, we are exploring the therapeutic potential of belumosudil in systemic sclerosis, a disease with similar manifestations to cGVHD. We continue to

      5/6/21 4:01:00 PM ET
      $KDMN
      Major Pharmaceuticals
      Health Care

    $KDMN
    Leadership Updates

    Live Leadership Updates

    See more
    • Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

      BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

      2/24/25 7:00:00 AM ET
      $AVIR
      $LQDA
      $KDMN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Major Pharmaceuticals
    • Kadmon Announces Appointment of Dr. Simon Cooper as Chief Medical Officer

      NEW YORK, NY / ACCESSWIRE / March 1, 2021 / Kadmon Holdings, Inc. (NASDAQ:KDMN) today announced the appointment of Simon Cooper, MBBS, as Senior Vice President, Chief Medical Officer, effective March 1, 2021. In this role, Dr. Cooper will oversee the Company's medical and clinical activities relating to the potential regulatory approval of belumosudil for chronic graft-versus-host disease and lead the Company's clinical team to advance the development of additional product candidates. Dr. Cooper succeeds John Ryan, M.D., Ph.D., who will remain with the Company and transition to the role of Executive Medical Director, Clinical and Regulatory Development, where he will continue to advise on c

      3/1/21 8:00:00 AM ET
      $KDMN
      Major Pharmaceuticals
      Health Care